2Akpek EK, Hasdiripi H, Christer WG, et al. A randomized trial of low dose, topical mitomycin C in the treatment of severe vernal keratoconjunctivitis. Ophthalmology, 2000, 107 (2): 263～269
3Nishiwaki - Dantas MCM, Dantas PE, Pezzutt S, et al. Surgical resection fo giant papillae and autologous conjunctival graft in patients with severe vernal keratoconjunctivitis and giant papillae. Ophthal Plast Reconstr Surg, 2000, 16 (6): 438～442
4BenEzra D, Pe'er J, Brodsky M, et al. Cyclosporine eyedrops for the treatment of severe vernal keratoconjunctives. Am J Ophthalmol,1986, 101 (3): 278～282
5Hikita N, Lopez JS, Chan CC, et al. Use o topical FK506 in a corneal graft rejection model in Lewis rats. Invest Ophthalmol Vis Sci,1997, 38 (5): 901～909
6Kino T, Hatanaka H, Miyata S, et al. FK506, a novel immunosuppressant isolate from a Streptomyces Ⅱ. immunosuppressive effect of FK506 in vitro. J Antibiot, 1987, 9:1256～1265
7Leonardi A, DeFranchis GF, et ald. Effects of cyclosporin A on human conjunctival fibroblasts. Arch Ophthalmol, 2001, 119 (10):1512～1517
2Bonini S.Lambiase A.Marchi S,et al. Vernal keratnconjunctivi-tis revisited.A case series of 195 patients with long-term follow- up [J]. Ophthalmology, 2000, 107 (6) : 1157- 1163.DOI: 10.1016/ S0161-6420(00)00092-0.
3Viehyanond P,Paeharn P,Pleyer U,et al. Vernal keratoeonjuneti- vitis:A severe allergic eye disease with remodeling changes[J]. Pediatric Allergy and Immunology, 2014, 25 (4) : 314"322.DOI: 10.1111/pai.12197.
4Jadad AR, Moore RA, Carroll D,et al. Assessing the quality of reports of randomized clinical trails: is blinding necessary[J]. Control Clin Trials, 1996, 17(1) : 1-12.DOI: 10.1016/0197-2456 (95)00134-4.
5Stang A.Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta- analyses [J]. Eur J Epidemiol, 2010, 25 (9) : 603 - 605,DOI: 10. lO07/s 10654-010-9491 -z.
6Vichyanond P, Tantimongkolsuk C, Dumrongkigchaiporn P,et al. Vernal keratoconjunctivitis: Result of a novel therapy with 0.1% topical ophthalmic FK-506 ointment[J]. J Allergy Clin Immunol, 2004,113 (2) : 355-358.DOI : 10.1016/j.jaci.2003.10.065.
8Labcharoenwongs P,Jirapongsananuruk O, Visitsunthorn N,et al. A double-masked comparison of 0.1% tacrolimus ointment and 2% cyclosporine eye drops in the treatment of vernal keratocon- junctivitis in children[Jl. Asian Pac J Allergy Immunol,2012, 30(3) : 177-184.
9Pucci N,Caputo R,di Grande L,et al. Tacrolimus vs. Cyclospo- rineeyedrops in severeeyclosporine-resistaut vernal keratoconjunc- tivitis : A randomized, comparative, double- blind, crossover study [J]. Pediatr Allergy Immunol, 2015, 26 (3) : 256 - 261.DOI: 10.111 I/paL 12360.
10Leonardi A,Sathe S, Bortolotti M, et al. Cytokines, matrix metal- loproteases, angiogenic and growth factors in tears of normal subjects and vernal keratoconjunctivitis patients [J]. Allergy, 2009,64(5) : 710-717.DOI: 10.1111/j.1398-9995.2008.01858.x.
